

## **REMARKS**

### **I. Examiner Interview**

On February 20, 2009, the undersigned, Mark Wilson, and Examiner Blessing M. Fubara participated in a telephonic interview to discuss the outstanding rejection issued in connection with the present application. Although no agreement was reached as to allowable subject matter, it is believed -- based on the telephonic interview -- that the present changes to the claims bring the claims closer to allowability, if not render them allowable.

### **II. Status of the Claims**

Claims 28-30, 38-44, 48, 49, 53 and 54 were previously pending.

Claims 29 and 56 have been amended and claims 1-27, 32-37, 55 and 57-85 have been canceled with the ability to prosecute the previously pending subject matter in one or more applications. Thus, claims 28-30, 38-44, 48, 49, 53 and 54 remain under consideration.

Support for the changes to the claims is identified below. Additional support other than that identified below may exist in the originally filed application for one or more changes to the claims.

Claim 29 has been amended to remove the explanation that the variables present in claim 29 were "previously defined." This explanation has been removed inasmuch as it is clear the variables in this dependent claim are fully defined in claim 28, the independent claim to which claim 29 depends.

Claim 56 has been amended to remove reference to "X<sup>1</sup>" in the chemical formulae in which X<sup>1</sup> for consistency between claims and to provide correct antecedent basis. In addition, like claim 29, claim 56 has been amended to remove the explanation that the variables present in claim 29 were "previously defined" (it being clear that the variables in this dependent claim are fully defined in claim 28, the independent claim to which claim 56 depends).

As support for the changes is found in the application as filed, no new matter is introduced by the entry of the above-identified changes. The changes to the claims are made for clarification purposes only should not be interpreted as acquiescence in any claim rejection.


### **III. Conclusion**

In view of the foregoing, Applicant submits that the pending claims satisfy the requirements of patentability and are therefore in condition for allowance. Reconsideration and withdrawal of all objections and rejections are respectfully requested and a prompt mailing of a Notice of Allowance is earnestly solicited.

If a telephone conference would expedite the prosecution of the subject application, the Examiner is requested to call the undersigned at (650) 620-5506.

Respectfully submitted on behalf of  
Nektar Therapeutics AL, Corporation,

Date: February 23, 2009

By:   
Mark A. Wilson  
Registration No. 43,275

### **CORRESPONDENCE ADDRESS:**

#### **Customer No. 21968**

Nektar Therapeutics  
201 Industrial Road  
San Carlos, California 94070  
(650) 631-3100 (Telephone)  
(650) 620-6395 (Facsimile)